Anergis (Switzerland)

Anergis is a Lausanne-based company specialising in the discovery and development of novel allergy vaccines targeting the most frequent allergies. Based on its proprietary Contiguous Overlapping Peptides (“COPs”) technology, Anergis is developing innovative desensitisation products that reproduce the full amino acid sequence of the allergen in separate long peptidic molecules. Anergis’ compounds do not cross-react with IgE, the antibody class responsible for allergic hypersensitivity and can therefore be safely administered at high doses to induce tolerance to the allergen after only a few injections, a distinct advantage compared to existing 3-5 year desensitisation treatments. Studies of Anergis’ compounds targeting bee venom and birch pollen allergies in both animals and humans have demonstrated excellent safety and immunogenicity. For more information, see


Case Studies